Top

Published in:

01-08-2012 | Review

Osteocyte regulation of bone mineral: a little give and take

Authors: G. J. Atkins, D. M. Findlay

Published in: Osteoporosis International | Issue 8/2012

Abstract

Osteocytes actively participate in almost every phase of mineral handling by bone. They regulate the mineralisation of osteoid during bone formation, and they are also a major RANKL-producing cell. Osteocytes are thus able to liberate bone mineral by regulating osteoclast differentiation and activity in response to a range of stimuli, including bone matrix damage, bone disuse and mechanical unloading, oestrogen deficiency, high-dose glucocorticoid and chemotherapeutic agents. At least some of these activities may be regulated by the osteocyte-secreted product, sclerostin. There is also mounting evidence that in addition to regulating phosphate homeostasis systemically, osteocytes contribute directly to calcium homeostasis in the mature skeleton. Osteocyte cell death and the local loss of control of bone mineralisation may be the cause of focal hypermineralisation of bone and osteopetrosis, as seen in aging and pathology. The sheer number of osteocytes in bone means that ‘a little give and take’ in terms of regulation of bone mineral content translates into a powerful whole organism effect.

Franz-Odendaal TA, Hall BK, Witten PE (2006) Buried alive: how osteoblasts become osteocytes. Dev Dyn 235:176–190PubMed

Batra N, Kar R, Jiang JX (2012) Gap junctions and hemichannels in signal transmission, function and development of bone. Biochim Biophys Acta (in press)

Marotti G, Ferretti M, Remaggi F, Palumbo C (1995) Quantitative evaluation on osteocyte canalicular density in human secondary osteons. Bone 16:125–128PubMed

Marotti G, Ferretti M, Muglia MA, Palumbo C, Palazzini S (1992) A quantitative evaluation of osteoblast–osteocyte relationships on growing endosteal surface of rabbit tibiae. Bone 13:363–368PubMed

Kamioka H, Honjo T, Takano-Yamamoto T (2001) A three-dimensional distribution of osteocyte processes revealed by the combination of confocal laser scanning microscopy and differential interference contrast microscopy. Bone 28:145–149PubMed

Bergwitz C, Juppner H (2010) Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med 61:91–104PubMed

Barragan-Adjemian C, Nicolella D, Dusevich V, Dallas MR, Eick JD, Bonewald LF (2006) Mechanism by which MLO-A5 late osteoblasts/early osteocytes mineralize in culture: similarities with mineralization of lamellar bone. Calcif Tissue Int 79:340–353PubMed

Atkins GJ, Welldon KJ, Wijenayaka AR, Bonewald LF, Findlay DM (2009) Vitamin K promotes mineralization, osteoblast-to-osteocyte transition, and an anticatabolic phenotype by {gamma}-carboxylation-dependent and -independent mechanisms. Am J Physiol Cell Physiol 297:C1358–C1367PubMed

Atkins GJ, Anderson PH, Findlay DM, Welldon KJ, Vincent C, Zannettino AC, O’Loughlin PD, Morris HA (2007) Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1 alpha,25-dihydroxyvitamin D3. Bone 40:1517–1528PubMed

10.

Atkins GJ, Welldon KJ, Halbout P, Findlay DM (2009) Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int 20:653–664PubMed

11.

Boyde A, Sela J (1978) Scanning electron microscope study of separated calcospherites from the matrices of different mineralizing systems. Calcif Tissue Res 26:47–49PubMed

12.

Midura RJ, Vasanji A, Su X, Wang A, Midura SB, Gorski JP (2007) Calcospherulites isolated from the mineralization front of bone induce the mineralization of type I collagen. Bone 41:1005–1016PubMed

13.

Murshed M, Harmey D, Millan JL, McKee MD, Karsenty G (2005) Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev 19:1093–1104PubMed

14.

Orimo H (2010) The mechanism of mineralization and the role of alkaline phosphatase in health and disease. J Nihon Med Sch 77:4–12PubMed

15.

Midura RJ, Wang A, Lovitch D, Law D, Powell K, Gorski JP (2004) Bone acidic glycoprotein-75 delineates the extracellular sites of future bone sialoprotein accumulation and apatite nucleation in osteoblastic cultures. J Biol Chem 279:25464–25473PubMed

16.

Gorski JP, Huffman NT, Chittur S, Midura RJ, Black C, Oxford J, Seidah NG (2011) Inhibition of proprotein convertase SKI-1 blocks transcription of key extracellular matrix genes regulating osteoblastic mineralization. J Biol Chem 286:1836–1849PubMed

17.

Atkins GJ, Rowe PS, Lim HP, Welldon KJ, Ormsby R, Wijenayaka AR, Zelenchuk L, Evdokiou A, Findlay DM (2011) Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J Bone Miner Res 26:1425–1436PubMed

18.

Addison WN, Masica DL, Gray JJ, McKee MD (2010) Phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage. J Bone Miner Res 25:695–705PubMed

19.

Rowe PS (2004) The wrickkened pathways of FGF23, MEPE and PHEX. Crit Rev Oral Biol Med 15:264–281PubMed

20.

Rowe PS, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, Rosen D, Cundy J, Navvab S, Chen D, Drezner MK, Quarles LD, Mundy GR (2004) MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34:303–319PubMed

21.

Guo R, Rowe PS, Liu S, Simpson LG, Xiao ZS, Quarles LD (2002) Inhibition of MEPE cleavage by PHEX. Biochem Biophys Res Commun 297:38–45PubMed

22.

Rowe PS, Garrett IR, Schwarz PM, Carnes DL, Lafer EM, Mundy GR, Gutierrez GE (2005) Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP). Bone 36:33–46PubMed

23.

Addison WN, Nakano Y, Loisel T, Crine P, McKee MD (2008) MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite: an inhibition regulated by PHEX cleavage of ASARM. J Bone Miner Res 23:1638–1649PubMed

24.

Martin A, David V, Laurence JS, Schwarz PM, Lafer EM, Hedge AM, Rowe PS (2008) Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology 149:1757–1772PubMed

25.

Yuan B, Takaiwa M, Clemens TL, Feng JQ, Kumar R, Rowe PS, Xie Y, Drezner MK (2008) Aberrant PHEX function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest 118:722–734PubMed

26.

Gorski JP (2011) Biomineralization of bone: a fresh view of the roles of non-collagenous proteins. Front Biosci 17:2598–2621PubMed

27.

Irie K, Ejiri S, Sakakura Y, Shibui T, Yajima T (2008) Matrix mineralization as a trigger for osteocyte maturation. J Histochem Cytochem 56:561–567PubMed

28.

Parfitt AM (2003) Misconceptions (3): calcium leaves bone only by resorption and enters only by formation. Bone 33:259–263PubMed

29.

Canalis E, Economides AN, Gazzerro E (2003) Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 24:218–235PubMed

30.

Bonewald LF (2011) The amazing osteocyte. J Bone Miner Res 26:229–238PubMed

31.

Chen D, Zhao M, Mundy GR (2004) Bone morphogenetic proteins. Growth Factors 22:233–241PubMed

32.

Canalis E (2009) Growth factor control of bone mass. J Cell Biochem 108:769–777PubMed

33.

Baron R, Rawadi G, Roman-Roman S (2006) Wnt signaling: a key regulator of bone mass. Curr Top Dev Biol 76:103–127PubMed

34.

ten Dijke P, Krause C, de Gorter DJ, Lowik CW, van Bezooijen RL (2008) Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg Am 90(Suppl 1):31–35PubMed

35.

Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, Dioszegi M, Dikkers FG, Hildering P, Willems PJ, Verheij JB, Lindpaintner K, Vickery B, Foernzler D, Van Hul W (2002) Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 39:91–97PubMed

36.

Staehling-Hampton K, Proll S, Paeper BW, Zhao L, Charmley P, Brown A, Gardner JC, Galas D, Schatzman RC, Beighton P, Papapoulos S, Hamersma H, Brunkow ME (2002) A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12–q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet 110:144–152PubMed

37.

Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D’Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23:860–869PubMed

38.

Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22:6267–6276PubMed

39.

Winkler DG, Yu C, Geoghegan JC, Ojala EW, Skonier JE, Shpektor D, Sutherland MK, Latham JA (2004) Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex. J Biol Chem 279:36293–36298PubMed

40.

Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, Reeve J (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19:1842–1844PubMed

41.

van Bezooijen RL, Bronckers AL, Gortzak RA, Hogendoorn PC, van der Wee-Pals L, Balemans W, Oostenbroek HJ, Van Hul W, Hamersma H, Dikkers FG, Hamdy NA, Papapoulos SE, Lowik CW (2009) Sclerostin in mineralized matrices and van Buchem disease. J Dent Res 88:569–574PubMed

42.

Chan BY, Fuller ES, Russell AK, Smith SM, Smith MM, Jackson MT, Cake MA, Read RA, Bateman JF, Sambrook PN, Little CB (2011) Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis. Osteoarthr Cartil 19:874–885PubMed

43.

Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19–26PubMed

44.

Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, Miyake A, Thesleff I, Itoh N (2003) Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 278:24113–24117PubMed

45.

Sutherland MK, Geoghegan JC, Yu C, Winkler DG, Latham JA (2004) Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts. Bone 35:448–454PubMed

46.

van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Lowik CW (2004) Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199:805–814PubMed

47.

Winkler DG, Sutherland MS, Ojala E, Turcott E, Geoghegan JC, Shpektor D, Skonier JE, Yu C, Latham JA (2005) Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J Biol Chem 280:2498–2502PubMed

48.

Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883–19887PubMed

49.

van Bezooijen RL, Svensson JP, Eefting D, Visser A, van der Horst G, Karperien M, Quax PH, Vrieling H, Papapoulos SE, ten Dijke P, Lowik CW (2007) Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 22:19–28PubMed

50.

Choi HY, Dieckmann M, Herz J, Niemeier A (2009) Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. PLoS One 4:e7930PubMed

51.

Leupin O, Piters E, Halleux C, Hu S, Kramer I, Morvan F, Bouwmeester T, Schirle M, Bueno-Lozano M, Ramos Fuentes FJ, Itin PH, Boudin E, De Freitas F, Jennes K, Brannetti B, Charara N, Ebersbach H, Geisse S, Lu CX, Bauer A, Van Hul W, Kneissel M (2011) Bone overgrowth-associated mutations in LRP4 impair sclerostin-facilitator function. J Biol Chem 286:19489–19500PubMed

52.

Leupin O, Halleux C, Morvan F, Hu S, Lu C, Bauer A, Kneissel M (2009) LRP4 is a novel osteoblast and osteocyte expressed specific facilitator of SOST-mediated inhibition of in vitro bone formation. J Bone Miner Res 24(Suppl 1). Available at: http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=c8cba0d3-a82c-4036-b4d8-29979e61e7a2

53.

Krause C, Korchynskyi O, de Rooij K, Weidauer SE, de Gorter DJ, van Bezooijen RL, Hatsell S, Economides AN, Mueller TD, Lowik CW, Ten Dijke P (2010) Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J Biol Chem 285:41614–41626PubMed

54.

Vincent C, Findlay DM, Welldon KJ, Wijenayaka AR, Zheng TS, Haynes DR, Fazzalari NL, Evdokiou A, Atkins GJ (2009) Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res 24:1434–1449PubMed

55.

Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, Bonewald LF, Kodama T, Wutz A, Wagner EF, Penninger JM, Takayanagi H (2011) Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 17:1231–1234PubMed

56.

Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O’Brien CA (2011) Matrix-embedded cells control osteoclast formation. Nat Med 17:1235–1241PubMed

57.

McGee MA, Findlay DM, Howie DW, Carbone A, Ward P, Stamenkov R, Page TT, Bruce WJ, Wildenauer CI, Toth C (2004) The use of OP-1 in femoral impaction grafting in a sheep model. J Orthop Res 22:1008–1015PubMed

58.

Cooper CW, Hirsch PF, Toverud SU, Munson PL (1967) An improved method for the biological assay of thyrocalcitonin. Endocrinology 81:610–616PubMed

59.

Parfitt AM (1998) Osteoclast precursors as leukocytes: importance of the area code. Bone 23:491–494PubMed

60.

Ejiri S, Ozawa H (1982) Scanning electron microscopic observations of rat tibia using the HCl-collagenase method. Arch Histol Jpn 45:399–404PubMed

61.

Colopy SA, Benz-Dean J, Barrett JG, Sample SJ, Lu Y, Danova NA, Kalscheur VL, Vanderby R Jr, Markel MD, Muir P (2004) Response of the osteocyte syncytium adjacent to and distant from linear microcracks during adaptation to cyclic fatigue loading. Bone 35:881–891PubMed

62.

Noble B (2003) Bone microdamage and cell apoptosis. Eur Cell Mater 6:46–55, discusssion 55PubMed

63.

Franssen BB, van Diest PJ, Schuurman AH, Kon M (2008) Drilling K-wires, what about the osteocytes? An experimental study in rabbits. Arch Orthop Trauma Surg 128:83–87PubMed

64.

Noble BS, Peet N, Stevens HY, Brabbs A, Mosley JR, Reilly GC, Reeve J, Skerry TM, Lanyon LE (2003) Mechanical loading: biphasic osteocyte survival and targeting of osteoclasts for bone destruction in rat cortical bone. Am J Physiol Cell Physiol 284:C934–C943PubMed

65.

Clark WD, Smith EL, Linn KA, Paul-Murphy JR, Muir P, Cook ME (2005) Osteocyte apoptosis and osteoclast presence in chicken radii 0–4 days following osteotomy. Calcif Tissue Int 77:327–336PubMed

66.

Herman BC, Cardoso L, Majeska RJ, Jepsen KJ, Schaffler MB (2010) Activation of bone remodeling after fatigue: differential response to linear microcracks and diffuse damage. Bone 47:766–772PubMed

67.

Cardoso L, Herman BC, Verborgt O, Laudier D, Majeska RJ, Schaffler MB (2009) Osteocyte apoptosis controls activation of intracortical resorption in response to bone fatigue. J Bone Miner Res 24:597–605PubMed

68.

Verborgt O, Tatton NA, Majeska RJ, Schaffler MB (2002) Spatial distribution of Bax and Bcl-2 in osteocytes after bone fatigue: complementary roles in bone remodeling regulation? J Bone Miner Res 17:907–914PubMed

69.

Mann V, Huber C, Kogianni G, Jones D, Noble B (2006) The influence of mechanical stimulation on osteocyte apoptosis and bone viability in human trabecular bone. J Musculoskelet Neuronal Interact 6:408–417PubMed

70.

Dodd JS, Raleigh JA, Gross TS (1999) Osteocyte hypoxia: a novel mechanotransduction pathway. Am J Physiol 277:C598–C602PubMed

71.

Aguirre JI, Plotkin LI, Stewart SA, Weinstein RS, Parfitt AM, Manolagas SC, Bellido T (2006) Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss. J Bone Miner Res 21:605–615PubMed

72.

Tatsumi S, Ishii K, Amizuka N, Li M, Kobayashi T, Kohno K, Ito M, Takeshita S, Ikeda K (2007) Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab 5:464–475PubMed

73.

Tomkinson A, Reeve J, Shaw RW, Noble BS (1997) The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J Clin Endocrinol Metab 82:3128–3135PubMed

74.

Emerton KB, Hu B, Woo AA, Sinofsky A, Hernandez C, Majeska RJ, Jepsen KJ, Schaffler MB (2010) Osteocyte apoptosis and control of bone resorption following ovariectomy in mice. Bone 46:577–583PubMed

75.

Shandala T, Ng YS, Hopwood B, Yip YC, Foster BK, Xian CJ (2012) The role of osteocyte apoptosis in cancer chemotherapy-induced bone loss. J Cell Physiol (in press)

76.

Findlay DM (2007) Vascular pathology and osteoarthritis. Rheumatology (Oxford) 46:1763–1768

77.

Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC (1998) Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102:274–282PubMed

78.

Weinstein RS, O’Brien CA, Almeida M, Zhao H, Roberson PK, Jilka RL, Manolagas SC (2011) Osteoprotegerin prevents glucocorticoid-induced osteocyte apoptosis in mice. Endocrinology 152:3323–3331PubMed

79.

Bronckers AL, Goei W, Luo G, Karsenty G, D’Souza RN, Lyaruu DM, Burger EH (1996) DNA fragmentation during bone formation in neonatal rodents assessed by transferase-mediated end labeling. J Bone Miner Res 11:1281–1291PubMed

80.

Findlay DM, Atkins GJ (2011) Relationship between serum RANKL and RANKL in bone. Osteoporos Int 22:2597–2602PubMed

81.

Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95:3597–3602PubMed

82.

Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:1329–1337PubMed

83.

Kurata K, Heino TJ, Higaki H, Vaananen HK (2006) Bone marrow cell differentiation induced by mechanically damaged osteocytes in 3D gel-embedded culture. J Bone Miner Res 21:616–625PubMed

84.

Al-Dujaili SA, Lau E, Al-Dujaili H, Tsang K, Guenther A, You L (2011) Apoptotic osteocytes regulate osteoclast precursor recruitment and differentiation in vitro. J Cell Biochem 112:2412–2423PubMed

85.

Kogianni G, Mann V, Noble BS (2008) Apoptotic bodies convey activity capable of initiating osteoclastogenesis and localized bone destruction. J Bone Miner Res 23:915–927PubMed

86.

Atkins GJ, Welldon KJ, Holding CA, Haynes DR, Howie DW, Findlay DM (2009) The induction of a catabolic phenotype in human primary osteoblasts and osteocytes by polyethylene particles. Biomaterials 30:3672–3681PubMed

87.

Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ (2011) Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One 6:e25900PubMed

88.

Palumbo C, Ferretti M, Ardizzoni A, Zaffe D, Marotti G (2001) Osteocyte-osteoclast morphological relationships and the putative role of osteocytes in bone remodeling. J Musculoskelet Neuronal Interact 1:327–332PubMed

89.

Zarrinkalam MR, Mulaibrahimovic A, Atkins GJ, Moore RJ (2012) Changes in osteocyte density correspond with changes in osteoblast and osteoclast activity in an osteoporotic sheep model. Osteoporos Int (in press)

90.

Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C (2009) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24:578–588PubMed

91.

Tian X, Setterberg RB, Li X, Paszty C, Ke HZ, Jee WS (2010) Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone 47:529–533PubMed

92.

Glass DA 2nd, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G (2005) Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8:751–764PubMed

93.

Kaneuji T, Ariyoshi W, Okinaga T, Toshinaga A, Takahashi T, Nishihara T (2011) Mechanisms involved in regulation of osteoclastic differentiation by mechanical stress-loaded osteoblasts. Biochem Biophys Res Commun 408:103–109PubMed

94.

Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH (2008) Mechanical stimulation of bone in vivo reduces osteocyte expression of sost/sclerostin. J Biol Chem 283:5866–5875PubMed

95.

Belanger LF, Belanger C, Semba T (1967) Technical approaches leading to the concept of osteocytic osteolysis. Clin Orthop Relat Res 54:187–196PubMed

96.

Qing H, Bonewald LF (2009) Osteocyte remodeling of the perilacunar and pericanalicular matrix. Int J Oral Sci 1:59–65PubMed

97.

Teti A, Zallone A (2009) Do osteocytes contribute to bone mineral homeostasis? Osteocytic osteolysis revisited. Bone 44:11–16PubMed

98.

Talmage RV, Mobley HT (2008) Calcium homeostasis: reassessment of the actions of parathyroid hormone. Gen Comp Endocrinol 156:1–8PubMed

99.

Haller AC, Zimny ML (1977) Effects of hibernation on interradicular alveolar bone. J Dent Res 56:1552–1557PubMed

100.

Tazawa K, Hoshi K, Kawamoto S, Tanaka M, Ejiri S, Ozawa H (2004) Osteocytic osteolysis observed in rats to which parathyroid hormone was continuously administered. J Bone Miner Metab 22:524–529PubMed

101.

Powell WF Jr, Barry KJ, Tulum I, Kobayashi T, Harris SE, Bringhurst FR, Pajevic PD (2011) Targeted ablation of the PTH/PTHrP receptor in osteocytes impairs bone structure and homeostatic calcemic responses. J Endocrinol 209:21–32PubMed

102.

Parfitt AM (1977) The cellular basis of bone turnover and bone loss: a rebuttal of the osteocytic resorption—bone flow theory. Clin Orthop Relat Res 127:236–247PubMed

103.

Barrett MG, Belinsky GS, Tashjian AH Jr (1997) A new action of parathyroid hormone. receptor-mediated stimulation of extracellular acidification in human osteoblast-like SaOS-2 cells. J Biol Chem 272:26346–26353PubMed

104.

Belinsky GS, Tashjian AH Jr (2000) Direct measurement of hormone-induced acidification in intact bone. J Bone Miner Res 15:550–556PubMed

105.

Bivi N, Bereszczak JZ, Romanello M, Zeef LA, Delneri D, Quadrifoglio F, Moro L, Brancia FL, Tell G (2009) Transcriptome and proteome analysis of osteocytes treated with nitrogen-containing bisphosphonates. J Proteome Res 8:1131–1142PubMed

106.

Qing H, Ardeshirour L, Dusevich V, Dallas M, Wysolmerski JJ, Bonewald LF (2008) Osteocytic perilacunar remodelling as a significant source of calcium during lactation. J Bone Miner Res 23:s401

107.

Nakano Y, Toyosawa S, Takano Y (2004) Eccentric localization of osteocytes expressing enzymatic activities, protein, and mRNA signals for type 5 tartrate-resistant acid phosphatase (TRAP). J Histochem Cytochem 52:1475–1482PubMed

108.

Yajima A, Inaba M, Tominaga Y, Nishizawa Y, Ikeda K, Ito A (2010) Increased osteocyte death and mineralization inside bone after parathyroidectomy in patients with secondary hyperparathyroidism. J Bone Miner Res 25:2374–2381PubMed

109.

Baylink D, Sipe J, Wergedal J, Whittemore OJ (1973) Vitamin D-enhanced osteocytic and osteoclastic bone resorption. Am J Physiol 224:1345–1357PubMed

110.

Roschger P, Paschalis EP, Fratzl P, Klaushofer K (2008) Bone mineralization density distribution in health and disease. Bone 42:456–466PubMed

111.

Kingsmill VJ, Boyde A (1998) Mineralisation density of human mandibular bone: quantitative backscattered electron image analysis. J Anat 192(Pt 2):245–256PubMed

112.

Hofstaetter JG, Roschger P, Klaushofer K, Kim HK (2010) Increased matrix mineralization in the immature femoral head following ischemic osteonecrosis. Bone 46:379–385PubMed

113.

Busse B, Djonic D, Milovanovic P, Hahn M, Puschel K, Ritchie RO, Djuric M, Amling M (2010) Decrease in the osteocyte lacunar density accompanied by hypermineralized lacunar occlusion reveals failure and delay of remodeling in aged human bone. Aging Cell 9:1065–1075PubMed

114.

Bell LS, Kayser M, Jones C (2008) The mineralized osteocyte: a living fossil. Am J Phys Anthropol 137:449–456PubMed

115.

Frost HM (1960) Micropetrosis. J Bone Joint Surg Am 42-A:144–150PubMed

116.

Gaudin-Audrain C, Gallois Y, Pascaretti-Grizon F, Hubert L, Massin P, Basle MF, Chappard D (2008) Osteopontin is histochemically detected by the AgNOR acid-silver staining. Histol Histopathol 23:469–478PubMed

117.

Kato Y, Windle JJ, Koop BA, Mundy GR, Bonewald LF (1997) Establishment of an osteocyte-like cell line, MLO-Y4. J Bone Miner Res 12:2014–2023PubMed

118.

Woo SM, Rosser J, Dusevich V, Kalajzic I, Bonewald LF (2011) Cell line IDG-SW3 replicates osteoblast-to-late-osteocyte differentiation in vitro and accelerates bone formation in vivo. J Bone Miner Res 26:2634–2646PubMed

119.

Wang W, Xu J, Du B, Kirsch T (2005) Role of the progressive ankylosis gene (ank) in cartilage mineralization. Mol Cell Biol 25:312–323PubMed

120.

Golub EE (2009) Role of matrix vesicles in biomineralization. Biochim Biophys Acta 1790:1592–1598PubMed

121.

Kalamajski S, Aspberg A, Lindblom K, Heinegard D, Oldberg A (2009) Asporin competes with decorin for collagen binding, binds calcium and promotes osteoblast collagen mineralization. Biochem J 423:53–59PubMed

122.

Gorski JP, Wang A, Lovitch D, Law D, Powell K, Midura RJ (2004) Extracellular bone acidic glycoprotein-75 defines condensed mesenchyme regions to be mineralized and localizes with bone sialoprotein during intramembranous bone formation. J Biol Chem 279:25455–25463PubMed

123.

Berendsen AD, Fisher LW, Kilts TM, Owens RT, Robey PG, Gutkind JS, Young MF (2011) Modulation of canonical Wnt signaling by the extracellular matrix component biglycan. Proc Natl Acad Sci U S A 108:17022–17027PubMed

124.

Huffman NT, Keightley JA, Chaoying C, Midura RJ, Lovitch D, Veno PA, Dallas SL, Gorski JP (2007) Association of specific proteolytic processing of bone sialoprotein and bone acidic glycoprotein-75 with mineralization within biomineralization foci. J Biol Chem 282:26002–26013PubMed

125.

Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE (2006) Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38:1310–1315PubMed

126.

Yadav MC, Simao AM, Narisawa S, Huesa C, McKee MD, Farquharson C, Millan JL (2011) Loss of skeletal mineralization by the simultaneous ablation of PHOSPHO1 and alkaline phosphatase function: a unified model of the mechanisms of initiation of skeletal calcification. J Bone Miner Res 26:286–297PubMed

127.

Yoshiko Y, Candeliere GA, Maeda N, Aubin JE (2007) Osteoblast autonomous Pi regulation via Pit1 plays a role in bone mineralization. Mol Cell Biol 27:4465–4474PubMed

128.

Terkeltaub RA (2001) Inorganic pyrophosphate generation and disposition in pathophysiology. Am J Physiol Cell Physiol 281:C1–C11PubMed

129.

Fedde KN, Blair L, Silverstein J, Coburn SP, Ryan LM, Weinstein RS, Waymire K, Narisawa S, Millan JL, MacGregor GR, Whyte MP (1999) Alkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia. J Bone Miner Res 14:2015–2026PubMed

Title: Osteocyte regulation of bone mineral: a little give and take
Authors: G. J. Atkins
D. M. Findlay
Publication date: 01-08-2012
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 8/2012
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-012-1915-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Osteocyte regulation of bone mineral: a little give and take

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2012

Short-term in vivo precision of BMD and parameters of trabecular architecture at the distal forearm and tibia

Vitamin D status and physical activity interact to improve bone mass in adolescents. The HELENA Study

The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures

Does the use of ACE inhibitors or angiotensin receptor blockers affect bone loss in older men?

The effects of smoking on bone metabolism

Resistive vibration exercise retards bone loss in weight-bearing skeletons during 60 days bed rest